These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 2890458)

  • 21. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors related to prescription dosage in Japanese psychiatric hospitals.
    Nawata S; Yamauchi K; Ikegami N
    Psychiatry Clin Neurosci; 2005 Feb; 59(1):70-6. PubMed ID: 15679543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial response to antipsychotic treatment: the patient with enduring symptoms.
    Emsley RA
    J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls.
    Jockers-Scherübl MC; Wolf T; Radzei N; Schlattmann P; Rentzsch J; Gómez-Carrillo de Castro A; Kühl KP
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1054-63. PubMed ID: 17482741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic dosage reduction in treatment-resistant schizophrenic patients.
    Van Putten T; Marshall BD; Liberman R; Mintz J; Kuehnel TG; Bowen L; Aravagiri M; Marder SR
    Psychopharmacol Bull; 1993; 29(2):315-20. PubMed ID: 7904763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Acute inpatient treatment of manias. Effects of independent variables on neuroleptic dosage and length of stay].
    Adler L; Ulrich M; Lehmann K; Nordeck I; Langer C; Thomas RS; Hajak G; Koller M
    Nervenarzt; 1996 Mar; 67(3):235-43. PubMed ID: 8901282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects.
    Altshuler LL; Ventura J; van Gorp WG; Green MF; Theberge DC; Mintz J
    Biol Psychiatry; 2004 Oct; 56(8):560-9. PubMed ID: 15476685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.
    Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A
    Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia.
    Krausz M; Moritz S; Lambert M; Naber D
    Int Clin Psychopharmacol; 2000 Mar; 15(2):77-81. PubMed ID: 10759338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paranoid/belligerence and neuroleptic dosage in newly admitted schizophrenic patients.
    Troisi A; Pasini A; de Angelis F; Spalletta G
    J Clin Psychopharmacol; 1997 Apr; 17(2):84-7. PubMed ID: 10950468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anesthetic management for schizophrenic patients on chronic phenothiazine therapy (author's transl)].
    Murakawa T; Matsuki A; Oyama T
    Masui; 1977 Oct; 26(10):1154-61. PubMed ID: 21976
    [No Abstract]   [Full Text] [Related]  

  • 32. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics.
    Rey MJ; Schulz P; Costa C; Dick P; Tissot R
    Int Clin Psychopharmacol; 1989 Apr; 4(2):95-104. PubMed ID: 2568378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Corneal and lens deposits due to treatment by phenothiazine type neuroleptics].
    Pouget R; Blayac JP; Largey B; Alric R; Castelnau D; Boulet J
    Ann Med Psychol (Paris); 1976 Mar; 1(3):403-7. PubMed ID: 7987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenothiazine levels in plasma and red blood cells. Their relationship to clinical improvement in schizophrenia.
    Casper R; Garver DL; Dekirmenjian H; Chang S; Davis JM
    Arch Gen Psychiatry; 1980 Mar; 37(3):301-5. PubMed ID: 6102458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction in antipsychotic drug dosage in mentally handicapped patients. A hospital study.
    Wressell SE; Tyrer SP; Berney TP
    Br J Psychiatry; 1990 Jul; 157():101-6. PubMed ID: 1975757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of phenothiazine neuroleptics by means of non-aqueous titrimetry].
    Barbato F; Cozzolino A; Silipo C; Vittoria A
    Boll Soc Ital Biol Sper; 1979 Oct; 55(19):2012-8. PubMed ID: 45304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioral Effects of Reducing the Daily Frequency of Phenothiazine Administration.
    Callahan EJ; Alevizos PN; Teigen JR; Newman H; Campbell MD
    Arch Gen Psychiatry; 1975 Oct; 32(10):1285-90. PubMed ID: 241307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between neuroleptic dosage and cognitive functioning in chronic schizophrenic patients.
    Hansen M; Paredes J; Koczapski A; Ledwidge B; Kogan C
    Clin Invest Med; 1987 Sep; 10(5):368-71. PubMed ID: 2890458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
    Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.